5/28
07:00 am
fhtx
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
Low
Report
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
5/24
02:11 am
fhtx
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Medium
Report
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
5/22
06:29 pm
fhtx
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline [Yahoo! Finance]
Low
Report
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline [Yahoo! Finance]
5/22
06:21 pm
fhtx
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
Low
Report
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
5/20
08:12 am
fhtx
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
5/20
07:58 am
fhtx
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
5/9
06:44 am
fhtx
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target [Yahoo! Finance]
Low
Report
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target [Yahoo! Finance]
5/7
08:01 am
fhtx
Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
5/6
09:48 am
fhtx
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
Medium
Report
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
5/6
07:26 am
fhtx
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update [Yahoo! Finance]
Low
Report
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update [Yahoo! Finance]
5/6
07:00 am
fhtx
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
Low
Report
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
5/1
08:00 am
fhtx
Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
4/16
07:19 am
fhtx
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer [Yahoo! Finance]
High
Report
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer [Yahoo! Finance]
4/16
07:00 am
fhtx
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
High
Report
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
4/10
08:05 am
fhtx
Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
4/10
08:05 am
fhtx
Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $13.00 price target on the stock.
Low
Report
Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $13.00 price target on the stock.
4/9
04:46 pm
fhtx
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs [Yahoo! Finance]
Low
Report
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs [Yahoo! Finance]
4/9
04:30 pm
fhtx
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Low
Report
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
4/9
06:57 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Low
Report
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
4/5
07:14 am
fhtx
Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference [Yahoo! Finance]
Low
Report
Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference [Yahoo! Finance]
4/5
07:00 am
fhtx
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
Low
Report
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
3/26
07:09 am
fhtx
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting [Yahoo! Finance]
Low
Report
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting [Yahoo! Finance]
3/26
07:00 am
fhtx
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
Low
Report
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting